The OneStart Americas 2016 programme began back in Oct 2015, with launch events in Boston, Houston and San Francisco. Within a two-month window, a record breaking 380+ applications had been submitted for thorough review and judging by SR One, Oxbridge Biotech Roundtable and the OneStart partners. Not only was the breadth of ideas vast but they also looked to tackle head on some of the most pressing medical challenges of the 21st century. From cancer and diabetes to neurodegeneration.
For the first time these solutions were equally distributed amongst the 4 main technology types. OneStart has shed it’s reputation as a predominantly therapeutics programme, with a significant rise in the number of ideas broadly categorized as medical devices, diagnostics and digital health / health IT solutions. For more information refer to our statistical breakdown of OneStart 2016.
In late December 2015 40 teams where chosen to progress to the next stage of the programme, these were the OneStart Americas 2016 semi-finalists. To support these teams OneStart is focused upon education and mentorship. We want to provide them with the guidance and education that will allow them to succeed.
This aim is very much reflected in the annual Americas Bootcamp. A 2-day event composed of seminars, panel discussions, pitching events and a plethora of networking opportunities. For the third year running this was held in the traditional startup hub of San Francisco.
The semi-finalists descended on Genentech Hall part of UCSF’s mission bay campus, in late February this year (19th and 20th February) to learn how to take their fantastic ideas and head straight towards the main goal of commercialisation. They were joined by a host of OneStart mentors and representatives from our partner network, who gave up their time for free with the sole purpose of helping to train the next generation of bio-entrepreneurs.
The 40 teams have now been reduced to the final top-10 (click here to view the Americas finalists). These teams will work tirelessly to perfect two assets, their extended business plans (10-pages) and slides decks (20-slides). Jens Eckstein, President of SR One and OneStart co-founder adds,
“This 2016 finalist group continues to demonstrate that entrepreneurship in the life sciences is alive and well – and young! We are so impressed by the breadth of applied science and technology as well as the maturity and energy the founding teams bring to bear. All in all good news for investors and patients!”
All 10 teams will pitch for the grand prize of $150,000 in Boston on May 26th that will be followed by our Gala Dinner at the Charles Hotel. A 3-course meal will be interspersed with short pitches from our finalists and messages from our partners. Tickets have been put aside for the ever-expanding OBR community. To attend, click here to register.
Lastly, we would like to extend our sincere gratitude and thanks to our OneStart Global: Takeda Ventures Inc., Bristol-Myers Squibb, GSK, Roche, AstraZeneca, MedImmune, Boehringer Ingelheim, Teva Pharmaceutical Industries, McKinsey & Co., Silicon Valley Bank and Americas: Sanofi and MassBio 2016 partners.
They are integral to the continued success and growth of the programme.
OneStart Americas 2016 – Finalists
Astraeus Technologies – Boston, United States.
We are creating an inexpensive, portable, accurate breath analysis device that will transform lung cancer screening.
Dynamic Boundaries Inc. – Ithaca, United States.
Our mission is to provide an effective treatment for osteoarthritis, one of the most prevalent and debilitating diseases.
Empire Biotechnologies – San Francisco, United States.
Developing the first orally delivered platform therapeutic for the many debilitating diseases of malabsorption.
InBrace – Huntingdon Beach, United States.
Behind-the-teeth, shape memory orthodontic solution w/ effectiveness of standard braces and comfort/ease of Invisalign.
Lelantus Medical – Palo Alto, United States.
Imagine you have a suspicious lesion in your lung, but no one can diagnose it. We have the solution.
Ovodex – Houston, United States.
Ovodex, accelerating cancer research and discovery, one egg at a time.
PathoVax – Baltimore, United States.
RGVax is a universal HPV vaccine that prevents all HPV disease with a cost-effective and established platform.
Sagacere Therapeutics – Toronto, Canada.
A promising treatment for primary progressive multiple sclerosis with neuroprotective and regenerative properties.
Suono Bio – Cambridge, United States.
Suono Bio is developing first-in-class devices for the ultra-rapid delivery of therapeutics to the GI tract.
Wickit Medical – Stanford, United States.
Wickit is an effective, low-cost solution to VAP, a lethal, hospital-acquired infection costing US healthcare $25B/year.
For more details about OneStart 2016, see www.onestart.co.
Notes for Editors
Interviews available with the CEO on request – please contact Jessica Sutcliffe on email@example.com.
About Oxbridge Biotech Roundtable (OBR) www.oxbridgebiotech.com
Oxbridge Biotech Roundtable was founded in 2011 with the aim of creating better ties between academia and industry. This is achieved through encouraging enhanced communication and consultancy between the two sectors, with a 30,000 strong network of academic and industrial professionals.
About SR One™ www.srone.com
SR One is the independent corporate healthcare venture capital fund of GlaxoSmithKline (GSK). Founded in 1985 they have invested over $830MM into the biotechnology sector, with a 35 strong public and private portfolio, investing globally in companies that will have a significant impact on medical care.
About OneStart www.onestart.co
OneStart is the world’s largest life sciences and healthcare startup accelerator programme. Founded in 2012 it aims to encourage entrepreneurship among young and disruptive healthcare innovators. Applications are open to all, from early to more developed businesses, whose idea focuses on improving human healthcare, irrespective of the type of technology. Participation is limited to individuals under the age of 36 and companies who have not raised more than $250,000 in dilutive funding.